Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Olanzapine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg

NCT00647777
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

NCT01617200
View directory record Official record
Conditions
Schizophrenia
Interventions
Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

NCT06315283
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-44749, Oral olanzapine
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Torrance, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

NCT02694328
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831, Olanzapine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

NCT01157351
View directory record Official record
Conditions
Schizophrenia
Interventions
paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
55
States / cities
Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 28, 2026, 10:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Glucose Regulation During Risperidone and Olanzapine Treatment

NCT00006195
View directory record Official record
Conditions
Schizophrenia
Interventions
risperidone, olanzapine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 11, 2006 · Synced Sep 28, 2026, 10:14 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

NCT00351000
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

NCT00113594
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Cerritos, California • National City, California • Poway, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2Phase 3 Interventional

Pediatric Oncology Nutrition Intervention Trial

NCT06175273
View directory record Official record
Conditions
Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
Interventions
Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care
Dietary Supplement · Drug · Other
Lead sponsor
Corey Hawes
Other
Eligibility
2 Years to 19 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 4 Interventional

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

NCT05741502
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Clozapine, Antipsychotics,Other (non-Clozapine)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

NCT01234779
View directory record Official record
Conditions
Schizophrenia
Interventions
bitopertin [RO4917838], olanzapine, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

NCT00490971
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Short Term Rescue Study of Olanzapine

NCT00186017
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Olanzapine/Zyprexa
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCT00347425
View directory record Official record
Conditions
Schizophrenia and Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

NCT00981526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Telmisartan, Placebo, Clozapine, Olanzapine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional

Treatment for First-Episode Schizophrenia

NCT00000374
View directory record Official record
Conditions
Schizophrenia
Interventions
Olanzapine, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
16 Years to 40 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
2
States / cities
Glen Oaks, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Olanzapine in Patients With Borderline Personality Disorder

NCT00091650
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Olanzapine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
15 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
9
States / cities
Atlanta, Georgia • Marietta, Georgia • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2006 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

NCT00512291
View directory record Official record
Conditions
Advanced Cancer
Interventions
Olanzapine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

NCT03030417
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

NCT00320489
View directory record Official record
Conditions
Schizophrenia
Interventions
olanzapine, olanzapine pamoate depot
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
13
States / cities
Escondido, California • National City, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2012 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 28, 2026, 10:14 AM EDT